Abstract-The shared properties of haematopoietic cytokines and their receptors have enabled the genetically engineered construction of several synthetic cytokines with increased haematopoietic activity and/ or more desirable pharmacological characteristics. Thrombocytopenia remains a significant cause of morbidity in cancer patients undergoing allogeneic or autologous bone marrow/ blood stem cell transplantation after myeloablative therapy including total body irradiation. Several in vitro, in vivo and preliminary clinical studies have demonstrated the efficacy of synthetic cytokines containing interleukin-3 in accelerating platelet recovery after radiotherapy-induced myelosuppression, enhancing G-CSF-mobilisation of CD34 positive cells for transplantation and increasing the ex-vivo expansion of myeloid and megakaryocytic progenitor cells. More randomised controlled clinical trials are needed to study the efficacy of the pre-transplant platelet mobilisation and the acceleration of the post-transplant platelet recovery. This also applies to cohort in vitro studies for expanding the production of CD41 + megakaryocytes from human bone marrow, mobilised peripheral blood and cord blood CD34 positive cells using myelopoietin as the only accepted synthetic cytokine containing interleukin-3.
INTRODUCTION
Human haematopoiesis, the complex biologic process responsible for the production of billions of mature blood cells each day, is regulated by many pleiotropic glyco-proteins named haematopoietic cytokines in the bone marrow. These cytokines are both survival and growth factors for haematopoietic stem, progenitor, precursor and mature cells [1] . The shared properties of these cytokines and their receptors have allowed the genetically engineered construction of several synthetic * Correspondence to be addressed to: Dr. H. T. Hassan, MD, PhD, Senior Lecturer of Haematology, School of Health Sciences, University of Wolverhampton, 62-68 Lichfield Street, Wolverhampton, WV1 1DJ, England, UK. Phone: +44-1902 +44- -321154, Fax: +44-1902 . [8]
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cytokines with increased haematopoietic activity and/ or more desirable pharmacological characteristics. Table 1 lists the single and combined synthetic cytokines generated during the last five years. Both daniplestim and pixykine were used in phase III clinical trials to mobilise CD34 positive cells for transplantation. Also, myelopoietin and daniplestim plus G-CSF were used in phase I/ II clinical trials to mobilise CD34 positive cells for transplantation. The other synthetic cytokines are undergoing both in vivo studies in non-human primates for haematopoietic reconstitution or mobilisation after cancer chemotherapy and in vitro studies for expansion of CD34 positive cells.
INTERLEUKIN-3 RECEPTOR AGONIST
Daniplestim is a synthetic, genetically engineered, interleukin-3 receptor agonist with a 20-fold greater in vitro clonogenic multi-lineage haematopoietic activity and only 2-fold greater inflammatory priming effect compared to recombinant human
